Mario E. Lacouture, MD, has joined the Treatment Support Program of the National Community Oncology Dispensing Association as director of the medical advisory board.
Mario E. Lacouture, MD
Mario E. Lacouture, MD, has joined the Treatment Support Program of the National Community Oncology Dispensing Association (NCODA) as director of the medical advisory board.
Lacouture is a board-certified dermatologist and serves as director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center in New York, New York. His research revolves around the dermatologic adverse effects of treatment with cancer therapeutics for patients with cancer and survivors. He has focused on both the recognition of these toxicities and the development of treatments, such as topical ointments, to help manage such events.
He is also the co-chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer.
Founder and executive director of NCODA, Michael Reff, exclaimed that it was “a great day for NCODA,” when Lacouture came on board to join the Treatment Support Program in March.
The NCODA Treatment Support Program aims to provide healthcare professionals with valuable resources to give to patients and caregivers regarding adherence and the management of adverse events when undergoing anticancer treatment. A priority of the program is the Treatment Support Kits which provide information for patients receiving treatment, and recommendations are currently available for more than 70 oral oncolytics. As director, Lacouture will guide the program committee and provide his expertise for the Treatment Support Kits and the program as a whole.
“Having an expert on the team who has seen first-hand how adverse effects of cancer treatments impact patient adherence is extremely important,” said Treatment Support Kit committee co-chair Chris Kepinski, PharmD, in a statement.